Table 3.
Association between MMP9 expression levels and clinicopathological features in 107 patients with cholangiocarcinoma
| Features | MMP9 Expression | P-value | |
|---|---|---|---|
|
| |||
| Low 51 (%) | High 56 (%) | ||
| Gender | 0.587 | ||
| Male | 33 (65%) | 39 (70%) | |
| Female | 18 (35%) | 17 (30%) | |
| Age (years) | 0.905 | ||
| <55 | 24 (47%) | 27 (48%) | |
| ≥55 | 27 (53%) | 29 (52%) | |
| Differentiation | 0.019 | ||
| Poorly | 12 (23%) | 20 (36%) | |
| Moderately | 33 (65%) | 36 (64%) | |
| Highly | 6 (12%) | 0 (0%) | |
| Vascular invasion | 0.523 | ||
| Yes | 17 (33%) | 22 (39%) | |
| No | 34 (67%) | 34 (61%) | |
| Lymph node metastasis | 0.017 | ||
| Yes | 22 (43%) | 37 (66%) | |
| No | 29 (57%) | 19 (34%) | |
MMP9, Matrix metalloproteinase-9.